Answers are grounded in this paper and cite their sources.
Systemic therapies for advanced renal cell carcinoma (aRCC) have evolved dramatically since the approvals of immuno-oncology (IO) agents.1 Thereafter, risk-based decision-making has become increasingly important to guide treatment selection. To date, there have been two widely-used nomograms for risk stratification of patients with aRCC: the Memorial Sloan Kettering Cancer Center (MSKCC) model2 and the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model.3 Both nomograms consist of similar clinical parameters such as short time from diagnosis to systemic therapy, poor performance status, low haemoglobin and high corrected calcium. In addition to these risk factors, the MSKCC model contains high lactate dehydrogenase (LDH), whereas the IMDC model contains neutrophils and platelets instead of LDH. In the era of IO combinations, several additional risk factors have been advocated including inflammatory markers such as neutrophil-to-lymphocyte ratio,4 C-reactive protein5 and absolute lymphocyte count,6 given that these biomarkers are closely linked to how IO agents use host immunity during antitumour immune response against aRCC.
No takes yet. Share an insight, caveat, or question.
Takemura et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: